SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

31 Jan 2024 Evaluate
The December 2023 quarter revenue stood at Rs. 10852.90 millions, up 24.05% as compared to Rs. 8748.90 millions during the corresponding quarter last year.Handsome Net Profit growth of 77.60% reported above the corresponding previous quarter figure of Rs. 2201.50 millions to Rs. 1239.60 millions.Operating profit surged to 3409.10 millions from the corresponding previous quarter of 1899.20 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 10852.90 8748.90 24.05 30450.50 25624.10 18.84 34112.70 31406.40 8.62
Other Income 137.30 305.10 -55.00 973.50 1443.00 -32.54 1327.50 1397.30 -5.00
PBIDT 3409.10 1899.20 79.50 9750.80 6507.50 49.84 8320.30 10306.20 -19.27
Interest 23.60 26.80 -11.94 53.80 40.20 33.83 52.30 91.20 -42.65
PBDT 3385.50 1872.40 80.81 9697.00 6467.30 49.94 8268.00 10215.00 -19.06
Depreciation 334.10 322.90 3.47 986.90 948.40 4.06 1269.50 1209.60 4.95
PBT 3051.40 1549.50 96.93 8710.10 5518.90 57.82 6998.50 9005.40 -22.29
TAX 849.90 309.90 174.25 2264.60 1103.80 105.16 1411.30 1806.80 -21.89
Deferred Tax 30.50 134.60 -77.34 87.10 55.20 57.79 -29.30 95.10 -130.81
PAT 2201.50 1239.60 77.60 6445.50 4415.10 45.99 5587.20 7198.60 -22.38
Equity 252.70 257.10 -1.71 252.70 257.10 -1.71 252.70 171.70 47.18
PBIDTM(%) 31.41 21.71 44.70 32.02 25.40 26.09 24.39 32.82 -25.67

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×